Journal article
M. Iwagami, K. Mansfield, J. Hayes, K. Walters, D. Osborn, L. Smeeth, D. Nitsch, L. Tomlinson
Clinical epidemiology, 2018
Clinical epidemiology, 2018
Semantic Scholar
DOI
PubMedCentral
PubMed
Cite
Cite
APA
Click to copy
Iwagami, M., Mansfield, K., Hayes, J., Walters, K., Osborn, D., Smeeth, L., … Tomlinson, L. (2018). Severe mental illness and chronic kidney disease: a cross-sectional study in the United Kingdom. Clinical Epidemiology.
Chicago/Turabian
Click to copy
Iwagami, M., K. Mansfield, J. Hayes, K. Walters, D. Osborn, L. Smeeth, D. Nitsch, and L. Tomlinson. “Severe Mental Illness and Chronic Kidney Disease: a Cross-Sectional Study in the United Kingdom.” Clinical epidemiology (2018).
MLA
Click to copy
Iwagami, M., et al. “Severe Mental Illness and Chronic Kidney Disease: a Cross-Sectional Study in the United Kingdom.” Clinical Epidemiology, 2018.
BibTeX Click to copy
@article{m2018a,
title = {Severe mental illness and chronic kidney disease: a cross-sectional study in the United Kingdom},
year = {2018},
journal = {Clinical epidemiology},
author = {Iwagami, M. and Mansfield, K. and Hayes, J. and Walters, K. and Osborn, D. and Smeeth, L. and Nitsch, D. and Tomlinson, L.}
}
Abstract
Objective We investigated the burden of chronic kidney disease (CKD) among patients with severe mental illness (SMI). Methods We identified patients with SMI among all those aged 25–74 registered in the UK Clinical Practice Research Datalink as on March 31, 2014. We compared the prevalence of CKD (two measurements of estimated glomerular filtration rate <60 mL/min/1.73 m2 for ≥3 months) and renal replacement therapy between patients with and without SMI. For patients with and without a history of lithium prescription separately, we used logistic regression to examine the association between SMI and CKD, adjusting for demographics, lifestyle characteristics, and known CKD risk factors. Results The CKD prevalence was 14.6% among patients with SMI and a history of lithium prescription (n = 4,295), 3.3% among patients with SMI and no history of lithium prescription (n = 24,101), and 2.1% among patients without SMI (n = 2,387,988; P < 0.001). The prevalence of renal replacement therapy was 0.23%, 0.15%, and 0.11%, respectively (P = 0.012). Compared to patients without SMI, the fully adjusted odds ratio for CKD was 6.49 (95% CI 5.84–7.21) for patients with SMI and a history of lithium prescription and 1.45 (95% CI 1.34–1.58) for patients with SMI and no history of lithium prescription. The higher prevalence of CKD in patients with SMI may, in part, be explained by more frequent blood testing as compared to the general population. Conclusion CKD is identified more commonly among patients with SMI than in the general population.
